ANRI
VC Fund
Tokyo, Japan
ANRI is a Japanese venture capital firm that mainly invests in seed and early-stage startups.
- Total investments:
- 315
- Last investment:
- Lead investor:
- 24%
- Fund size:
- $102M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries ANRI invests in
Stages ANRI invests in
Countries ANRI invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Round size
- Seed
- $268k–$9.9M
- Series A
- $967k–$41M
- Venture - Series Unknown
- $616k–$9.1M
Investment Focus
Industry
- Software 30 (10%)
- Health Care 26 (8%)
- Information Technology 26 (8%)
- Medical 24 (8%)
- Internet 19 (6%)
Stage
- Seed 136 (43%)
- Series A 60 (19%)
- Venture - Series Unknown 32 (10%)
- Series B 15 (5%)
- Funding Round 13 (4%)
Country
- Japan 202 (64%)
- United States 7 (2%)
- Indonesia 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Anri Samata
Partner; Founder & General Partner
|
Partner; Founder & General Partner | Total investments: 15 | Find email | |
Anri Samata
Founder & General Partner
|
Founder & General Partner | Total investments: 10 | Find email | |
Junichiro Kono
General Partner
|
General Partner | Total investments: 15 | Find email | |
Kazuhiro Sakakibara
Senior Associate
|
Senior Associate | Total investments: 5 | Find email | |
Masahiro Sameshima
General Partner
|
General Partner | Total investments: 9 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Typewriter Therapeutics, Inc. develops mRNA-based gene therapies using a gene writing, or gene writing, platform for precise insertion of therapeutic genes into the genome. The company builds on transposon-based technologies originating from research by Professor Emeritus Haruhiko Fujiwara at the University of Tokyo. Its programs focus on all‑RNA,nonviral gene writing systems that repurpose natural genetic elements to address severe genetic disorders with limited treatment options. Typewriter Therapeutics conducts research and development across its U.S. and Japan operations and collaborates with investors and partners to advance genetic medicine candidates toward the clinic. | $56.3M / Series A / Sep 02, 2026 | ||
| Arrowsmith is committed to unlocking the full potential of bacteriophages to revolutionize the treatment of bacterial infectious diseases. Through transformative science, Arrowsmith strive to create a world free from the pain and fear caused by antimicrobial resistance. | $6.5M / Series A / Jun 22, 2026 | ||
| HANAMII is a creative and marketing company that offers digital marketing, branding, business support services, and social media marketing. | Seed / Jun 16, 2026 | ||
| xCARE specializes in the development and commercialization phases of the pharmaceutical and medical device industries. | $3.7M / Series A / Jun 08, 2026 | ||
| Atom is a humanoid robot built platform. Its bipedal, dual-armed robots are designed not just as industrial tools but as collaborators that expand human capability. By combining advanced Physical AI—environmental perception, judgment, and action planning—with robust robotic hardware, Atom is creating adaptive agents capable of working acrossdiverse settings to augment or, where appropriate, replace human labor. The company positions these robots as a next step in societal evolution: a new class of machines that learn and behave in human-like ways to advance productivity, safety, and quality of life. | $18.8M / Seed / May 27, 2026 | ||
| Factory X is an information technology company that helps to increase value manufacturers with the inventory strategy model. | $628.4K / Seed / May 22, 2026 | ||
| YStory is a digital health firm that uses AI and medical science to improve women's health during menopause. | Seed / Apr 27, 2026 | ||
| Grafto operates “Mylo Magazine,” a platform dedicated to sharing and promoting trend culture, where readers can explore the latest developments in lifestyle, fashion, art, and emerging cultural movements through engaging and curated content. | $628.5K / Seed / Mar 17, 2026 | ||
| Redelta provides a technology‑enabled platform and advisory services for cross‑border mergers and acquisitions between Japan and Southeast Asia. The service operates an In‑Out marketplace that connects corporate buyers, business owners, and investors pursuing expansion or divestiture. Engagements include deal sourcing, preliminary screening,valuation viewpoints, and coordination with local professionals throughout the transaction process. Sector and country reports, market briefs, and knowledge articles support planning and investment theses. The platform centralizes mandates and opportunities and facilitates communication between counterparties to accelerate initial discussions. Consulting support also addresses partner introductions and market entry considerations linked to post‑transaction growth. | $764.1K / Venture - Series Unknown / Mar 05, 2026 | ||
| Anaut specializes in software development utilizing artificial intelligence for surgical support in surgical medicine. | Series B / Mar 01, 2026 | ||
| See all 315 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does ANRI invest in?
ANRI invests primarily in Software, Health Care and Information Technology startups, most often at Seed and Series A stage. Most of the 315 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does ANRI invest in?
ANRI typically joins rounds of $268k–$9.9M at Seed, $967k–$41M at Series A and $616k–$9.1M at Venture - Series Unknown. These are whole funding-round sizes, not ANRI's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds ANRI took part in.
How do I contact ANRI?
Public channels for ANRI include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at ANRI?
The team at ANRI includes Anri Samata (Partner; Founder & General Partner), Anri Samata (Founder & General Partner) and Junichiro Kono (General Partner), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
